

Sage Therapeutics Inc (SAGE) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/S1A3ABDBEA8EN.html>

Date: September 2021

Pages: 61

Price: US\$ 125.00 (Single User License)

ID: S1A3ABDBEA8EN

Abstracts

Sage Therapeutics Inc (SAGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sage Therapeutics Inc (Sage) is a clinical-stage biopharmaceutical company that discovers, develops and markets therapeutics and medicines for central nervous system (CNS) disorders. It develops drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors of NMDA and GABA. Its flagship product Zulresso (brexanolone) is a proprietary intravenous (IV) formulation administered for the treatment of postpartum depression (PPD). The company also has various pipeline products for the treatment of indications such as postpartum depression, major depressive disorders, bipolar depression, Parkinson's disease, insomnia, epileptiform disorders and NMDA hypofunction. The company through its subsidiaries operates in the US, Bermuda, Germany, Switzerland, England and Wales. Sage is headquartered in Cambridge, Massachusetts, the US.

Sage Therapeutics Inc Key Recent Developments

Sep 21,2021: Sage Therapeutics appoints Chris Benecchi as Chief Commercial Officer

Aug 03,2021: Sage Therapeutics Announces Second Quarter 2021 Financial Results and **Highlights** Pipeline and Business Progress

May 20,2021: Sage Therapeutics Joins MTV Entertainment Group and More Than

1,300 Leading Organizations to Participate in Inaugural Mental Health Action Day
May 04,2021: Sage Therapeutics Announces First Quarter 2021 Financial Results and
Highlights Pipeline and Business Progress

Apr 20,2021: Sage Therapeutics to Report First Quarter 2021 Financial Results on
Tuesday, May 4, 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage,

financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Sage Therapeutics Inc - Key Facts
Sage Therapeutics Inc - Key Employees
Sage Therapeutics Inc - Key Employee Biographies
Sage Therapeutics Inc - Major Products and Services
Sage Therapeutics Inc - History
Sage Therapeutics Inc - Company Statement
Sage Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Sage Therapeutics Inc - Business Description
R&D Overview
Sage Therapeutics Inc - Corporate Strategy
Sage Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Sage Therapeutics Inc - Strengths
Sage Therapeutics Inc - Weaknesses
Sage Therapeutics Inc - Opportunities
Sage Therapeutics Inc - Threats
Sage Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Sage Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 21, 2021: Sage Therapeutics appoints Chris Benecchi as Chief Commercial Officer

Aug 03, 2021: Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

May 20, 2021: Sage Therapeutics Joins MTV Entertainment Group and More Than 1,300 Leading Organizations to Participate in Inaugural Mental Health Action Day

May 04, 2021: Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

Apr 20, 2021: Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021

Mar 16, 2021: Sage Therapeutics Announces Departure of Chief Operating Officer

Feb 24, 2021: Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress

Feb 11, 2021: Sage Therapeutics to Present at Upcoming Investor Conferences

Feb 10, 2021: Sage Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021

Jan 07, 2021: Sage Therapeutics provides 2021 corporate strategy update at J.P. Morgan Healthcare Conference

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Sage Therapeutics Inc, Key Facts
Sage Therapeutics Inc, Key Employees
Sage Therapeutics Inc, Key Employee Biographies
Sage Therapeutics Inc, Major Products and Services
Sage Therapeutics Inc, History
Sage Therapeutics Inc, Subsidiaries
Sage Therapeutics Inc, Key Competitors
Sage Therapeutics Inc, Ratios based on current share price
Sage Therapeutics Inc, Annual Ratios
Sage Therapeutics Inc, Annual Ratios (Cont...1)
Sage Therapeutics Inc, Interim Ratios
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Sage Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Sage Therapeutics Inc, Performance Chart (2016 - 2020)

Sage Therapeutics Inc, Ratio Charts

Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Sage Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Sage Therapeutics Inc (SAGE) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/S1A3ABDBEA8EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S1A3ABDBEA8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970